 "JB Chemicals surges 12%, hits record high on strong Q3 performance")
Shares of JB Chemicals & Pharmaceuticals, on Thursday, surged 12 per cent intra-day to Rs 1,213 on the BSE after reporting more-than-doubled net profit at Rs 154.30 for the December quarter (Q3FY21), on the back of strong operational performance. The company had profit of Rs 66.40 crore in the year-ago quarter. The stock surpassed its previous high of Rs 1,150, touched on September 21, 2020.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew 90.8 per cent year on year (YoY) at Rs 171 crore, margin improved 1030 basis points (bps) to 31.2 per cent during the quarter, driven by growth and operating leverage. Revenue from operations rose 27.9 per cent YoY at Rs 548.2 crore. The reported topline in the quarter also includes revenues deferred from the September quarter (Q2FY21).
The management said that the India business continues to witness a positive trend in the chronic segment and the company is among the fastest growing companies in Indian pharmaceuticals market (IPM).
The operational and revenue momentum continues – with strong contributions from domestic formulations and international business. The domestic Formulations maintain secular outperformance compared to IPM growth rates, driven by strength in chronic segments and expanding prescriber coverage. With improved doctor/prescriber coverage trends and anticipated revival in acute, expect the healthy domestic trend to continue, the company said.
Meanwhile, the company's board of directors has declared interim dividend of Rs 8.50 per equity share of face value of Rs 2 (425 per cent) for the financial year 2020-21. The dividend will be remitted/ dividend warrants will be dispatched on March 5, 2021, it said.
At 09:34 am, the stock was trading 9 per cent higher at Rs 1,177 on the BSE, as compared to 0.07 per cent decline in the S&P BSE Sensex. A combined around 780,000 equity shares had changed hands on the counter on the NSE and BSE.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew 90.8 per cent year on year (YoY) at Rs 171 crore, margin improved 1030 basis points (bps) to 31.2 per cent during the quarter, driven by growth and operating leverage. Revenue from operations rose 27.9 per cent YoY at Rs 548.2 crore. The reported topline in the quarter also includes revenues deferred from the September quarter (Q2FY21).
The management said that the India business continues to witness a positive trend in the chronic segment and the company is among the fastest growing companies in Indian pharmaceuticals market (IPM).
The operational and revenue momentum continues – with strong contributions from domestic formulations and international business. The domestic Formulations maintain secular outperformance compared to IPM growth rates, driven by strength in chronic segments and expanding prescriber coverage. With improved doctor/prescriber coverage trends and anticipated revival in acute, expect the healthy domestic trend to continue, the company said.
Meanwhile, the company's board of directors has declared interim dividend of Rs 8.50 per equity share of face value of Rs 2 (425 per cent) for the financial year 2020-21. The dividend will be remitted/ dividend warrants will be dispatched on March 5, 2021, it said.
At 09:34 am, the stock was trading 9 per cent higher at Rs 1,177 on the BSE, as compared to 0.07 per cent decline in the S&P BSE Sensex. A combined around 780,000 equity shares had changed hands on the counter on the NSE and BSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%